drugset
drugset / Trial / NCT04933565

First in Human Study of ORG-129 in Healthy Volunteers

NCT04933565 ↗

Phase 1 Completed 81 enrolled Origo Biopharma
RandomizedSequentialDouble-blindTreatment

Summary

The current study is performed to characterize the safety, tolerability and pharmacokinetics of ORG-129 after oral intake in healthy male and female volunteers after single ascending and multiple ascending doses.

Timeline

Start
2021-06-01
Primary completion
2022-12-12
Completion
2023-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ORG-129 Unknown — Oral

Indications

No indication recorded.